Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI (maralixibat). This new formulation is for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
The tablet form provides an additional treatment option, offering flexibility for patients and physicians. It allows for liquid dosing for the youngest patients and a convenient one-tablet per dose option for older patients, addressing diverse patient needs.
LIVMARLI tablets are planned to be available in June through Mirum Access Plus. This product enhancement is expected to positively impact patients' lives by offering increased convenience, potentially driving further adoption and market penetration for LIVMARLI.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.